tiprankstipranks
Trending News
More News >
Cts Corp. (CTS)
NYSE:CTS
US Market

CTS (CTS) Earnings Dates, Call Summary & Reports

Compare
127 Followers

Earnings Data

Report Date
Apr 23, 2026
Before Open (Confirmed)
Period Ending
2026 (Q1)
Consensus EPS Forecast
0.52
Last Year’s EPS
0.44
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Feb 10, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
Overall the call emphasized clear progress on diversification, margin expansion, strong cash generation, and robust growth in medical and industrial end markets. These positives were tempered by transportation headwinds (notably in China and commercial vehicles), timing-related softness in SideQuest/defense bookings, and modest sequential revenue softness. Management provided modestly positive guidance for 2026 while acknowledging macro and supply-chain risks.
Company Guidance
For full-year 2026, assuming continuation of current market conditions, management guided sales of $550 million to $580 million and adjusted diluted EPS of $2.30 to $2.45; they expect solid demand across diversified end markets (medical momentum with increased therapeutic volumes in 2026, aerospace & defense revenue growth supported by backlog and SideQuest normalization, and industrial/distribution to remain healthy), while transportation production volumes are forecast to be flat to marginally down in line with IHS light vehicle estimates (North America 15–16 million units, Europe 16–17 million, China ~32 million), commercial vehicle demand generally soft with potential improvement in H2, floor‑hinge revenue not expected until 2028, next‑generation smart actuator qualification is progressing with further enhancements planned for 2026, and management noted no significant immediate supply‑chain disruptions from rare earths or semiconductors.
Quarterly and Full-Year Revenue Growth
Q4 sales of $137 million, up 9% year-over-year; full-year 2025 revenue of $541 million, up 5% versus $515 million in 2024.
Diversification Momentum
Diversified end markets grew 16% year-over-year in Q4 and were 59% of company revenue in Q4 (57% for the full year), supporting higher-margin revenue mix.
Medical Market Outperformance
Medical Q4 sales increased 41% year-over-year; full-year medical sales of $85 million, up 21% from $70 million in 2024; medical bookings up 37% in the quarter and book-to-bill ~1.07 for 2025.
Industrial Recovery and Bookings Strength
Industrial Q4 sales up 16% year-over-year; full-year industrial sales £140 million, up 12% from £125 million in 2024; industrial bookings up 22% in the quarter and full-year book-to-bill 1.11.
Aerospace & Defense Full-Year Growth and Strategic Wins
Aerospace & defense full-year sales $83 million, up 20% year-over-year, with multiple naval sonar/hydrophone and RF filter awards and new customers added, supporting future backlog.
Margin and Profitability Expansion
Adjusted gross margin expanded ~150 basis points (Q4 adjusted gross margin 39.1%; full-year adjusted gross margin 38.5%); adjusted EBITDA margin improved to 22.8%, up 40 basis points year-over-year.
Earnings Improvement
Q4 adjusted diluted EPS $0.62 versus $0.50 a year ago; full-year adjusted diluted EPS $2.23 versus $2.12 in 2024; Q4 GAAP diluted EPS $0.67 versus $0.38 prior-year quarter.
Strong Cash Generation and Capital Return
Operating cash flow of $29 million in Q4 and $102 million for the full year; cash balance $82 million and borrowings $58 million; repurchased ~398k shares (~$17 million) in Q4 and ~1.4 million shares (~$57 million) for the year; total returned $62 million to shareholders with $90 million remaining authorization.
Book-to-Bill and Backlog Indicators
Company-level book-to-bill of 1.03 in Q4 and 1.04 for the full year, indicating sustained customer demand; total book business approximately $1 billion at quarter end.
2026 Financial Guidance
Management provided 2026 guidance of $550 million to $580 million in sales and adjusted diluted EPS of $2.30 to $2.45, indicating expected modest growth and margin expansion.

CTS (CTS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CTS Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Apr 23, 2026
2026 (Q1)
0.52 / -
0.44
Feb 10, 2026
2025 (Q4)
0.60 / 0.62
0.5316.98% (+0.09)
Oct 28, 2025
2025 (Q3)
0.61 / 0.60
0.63-4.76% (-0.03)
Jul 24, 2025
2025 (Q2)
0.55 / 0.57
0.545.56% (+0.03)
Apr 30, 2025
2025 (Q1)
0.49 / 0.44
0.47-6.38% (-0.03)
Feb 04, 2025
2024 (Q4)
0.54 / 0.53
0.4712.77% (+0.06)
Oct 29, 2024
2024 (Q3)
0.54 / 0.63
0.5416.67% (+0.09)
Jul 30, 2024
2024 (Q2)
0.53 / 0.54
0.59-8.47% (-0.05)
May 01, 2024
2024 (Q1)
0.41 / 0.47
0.61-22.95% (-0.14)
Feb 06, 2024
2023 (Q4)
0.46 / 0.47
0.56-16.07% (-0.09)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CTS Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 10, 2026
$55.58$57.29+3.08%
Oct 28, 2025
$42.40$40.47-4.55%
Jul 24, 2025
$40.36$41.92+3.86%
Apr 30, 2025
$39.78$37.97-4.54%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cts Corp. (CTS) report earnings?
Cts Corp. (CTS) is schdueled to report earning on Apr 23, 2026, Before Open (Confirmed).
    What is Cts Corp. (CTS) earnings time?
    Cts Corp. (CTS) earnings time is at Apr 23, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CTS EPS forecast?
          CTS EPS forecast for the fiscal quarter 2026 (Q1) is 0.52.